Matlou Mokgotho | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Matlou Mokgotho | Drug Discovery and Development | Best Researcher Award

Lecturer at Sefako Makgatho Health Science University | South Africa

Prof. Dr. Matlou Mokgotho is a distinguished biochemist and academic leader with over two decades of experience in higher education, research, and community development. Currently a Senior Lecturer at Tshwane University of Technology, he has previously served as Professor and Head of Department of Biochemistry at the University of Limpopo. His expertise spans molecular biology, proteomics, bioenergetics, enzymology, and mammalian cell cultures. Beyond academia, Dr. Mokgotho has actively contributed to community health awareness initiatives, youth leadership, and ethical oversight in research and professional bodies. His leadership, research excellence, and dedication to mentorship continue to inspire future scientists in South Africa.

Publication Profile 

Orcid

Education 

Prof. Dr. Matlou Mokgotho holds a Doctor of Philosophy in Biochemistry from the University of Limpopo, conferred. He earned his Master of Science in Biochemistry his Bachelor of Science Honours in Biochemistry  both from the University of the North. He also completed a Bachelor of Science in Biochemistry and Microbiology at the same institution. His academic foundation was laid at Seshigo High School, where he obtained his Senior Certificate. This strong educational background provided him with the knowledge and skills to excel in biochemical sciences and academic leadership.

Experience 

Prof. Dr. Matlou Mokgotho career spans roles from tutor to senior lecturer, professor, and department head. He began lecturing in Biochemistry at the University of the North before joining the University of Limpopo, where he advanced to Professor and Head of Department. His teaching portfolio covers biochemistry, molecular biology, proteomics, cell culture, and bioenergetics. He also served as CEO of Milestevens Development and Properties, showcasing leadership in management. Currently, he is Senior Lecturer at Tshwane University of Technology and a module critical reader at UNISA. His responsibilities include teaching, research coordination, and academic mentorship.

Awards and Honors 

Prof. Dr. Matlou Mokgotho has been recognized for his academic, community, and leadership contributions. He received certificates for AIDS Awareness campaigns and laboratory assistance during his early career, highlighting his dedication to education and health promotion. His leadership in youth and church organizations earned him certificates of moral leadership and community service, while his active role in HIV/AIDS awareness workshops reflected his commitment to social impact. As a council member of the South African Dental Technician Council, he contributed to professional ethics and governance. These accolades underscore his commitment to advancing science, leadership, and community development.

Research Focus 

Prof. Dr. Matlou Mokgotho research focuses on biochemistry, molecular biology, and proteomics, with a special interest in bioenergetics, protein structure-function relationships, and mammalian cell cultures. His work bridges fundamental and applied science, exploring enzymology, molecular mechanisms, and the applications of cell cultures in medical research. He has also contributed to developing experimental methodologies and training students in proposal writing, research principles, and dissertation development. His commitment to advancing biochemistry is reflected in his integration of teaching, research, and community engagement, with a strong emphasis on preparing students for careers in molecular science and addressing health challenges through biotechnological approaches.

Publication Top Notes

Jun Mao | Psychopharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Jun Mao | Psychopharmacology | Best Researcher Award

Dr. Jun Mao at Sichuan University | China

Dr. Jun Mao is a distinguished researcher in the field of biomedicine, pharmacology, and computational drug design. With a strong academic foundation in genetic and cell engineering, cheminformatics, and bioinformatics, he has dedicated his career to advancing innovative methodologies for drug discovery and psychological health. His work integrates cutting-edge techniques such as molecular modeling, machine learning, and deep learning to address complex biomedical challenges. Dr. Mao’s research has led to impactful contributions in developing prediction models, web-based tools, and novel therapeutic candidates, bridging the gap between computation and clinical application. His publications are recognized in high-impact scientific journals.

Publication Profile 

Orcid

Education 

Dr. Jun Mao pursued his education at renowned Chinese institutions, building expertise in both experimental and computational biomedical sciences. He studied Genetic and Cell Engineering at Chengdu Medical College, where he developed a strong foundation in biotechnology and molecular biology. At Northwest Normal University, he advanced into Drug Design and Molecular Modelling, deepening his knowledge in structural biology and computational chemistry. His academic journey continued at Sichuan University, specializing in Cheminformatics and Bioinformatics, where he honed skills in data-driven medical research and computational approaches to drug discovery. This multidisciplinary training uniquely equipped him to explore challenges in medicine and pharmacology.

Experience 

Dr. Jun Mao has accumulated extensive experience across the intersection of computational science, pharmacology, and biomedical innovation. His professional endeavors focus on utilizing molecular modeling and deep learning to identify therapeutic targets and develop novel drugs. He has contributed to creating medical and psychological databases, designing web-based platforms, and implementing machine learning models for predictive medicine. His research includes identifying new scaffolds for microtubule stabilizers, DNA topoisomerase inhibitors, and PDE inhibitors. Beyond pharmacology, he has also developed computational tools to assess toxicity and neuropsychological disorders, demonstrating his versatility. His cross-disciplinary expertise has significantly advanced predictive modeling and precision medicine.

Awards and Honors 

Dr. Jun Mao has earned recognition for his outstanding contributions to biomedicine, computational pharmacology, and machine learning applications in healthcare. His research publications in internationally acclaimed journals, including Nature Communications and Chemico-Biological Interactions, highlight the novelty and global impact of his work. He has been honored with academic awards for innovation in computational drug design, and his contributions have received acclaim for bridging computation with clinical translational applications. His development of interpretable prediction models, web tools, and virtual screening platforms has established him as a thought leader in computational pharmacology, earning invitations to collaborative research projects and academic partnerships.

Research Focus 

Dr. Jun Mao research focuses on the application of computational intelligence to medicine and pharmacology. He integrates machine learning, deep learning, and molecular modeling to identify new drug targets, study molecular mechanisms, and develop novel therapeutic agents. His work explores psychoinformatics to predict mental health disorders, assisting clinical applications through interpretable computational models. He develops specialized web-based tools, databases, and prediction frameworks to enhance drug safety and toxicity assessments. His efforts extend to anticancer drug discovery, neurotoxicity evaluation, and stem cell proliferation studies. By uniting computation with biomedical sciences, his research drives innovation in precision and predictive medicine.

Publication Top Notes

Luana Fioriti | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Luana Fioriti | Pharmacology | Best Researcher Award

Laboratory Director at Istiuto di Riceerche Farmacologiche Mario Negri | Italy

Assoc. Prof. Dr. Luana Fioriti is a distinguished neuroscientist recognized for her groundbreaking research on prion-like proteins, synaptic plasticity, and neurodegenerative disorders. She has served in leading roles at Columbia University and the “Mario Negri” Institute in Milan, where she heads her laboratory in the Department of Neuroscience. With extensive expertise in protein aggregation, memory mechanisms, and disease-related pathways, Dr. Fioriti has contributed significantly to advancing knowledge in molecular neuroscience. Her pioneering work has been published in leading scientific journals and supported by prestigious awards and fellowships. She continues to drive innovation in translational neurobiology research.

Publication Profile 

Orcid

Education 

Assoc. Prof. Dr. Luana Fioriti earned her PhD in Neuroscience at the Mario Negri Institute and Open University, Italy, where she investigated abnormal forms of prion proteins in inherited prion diseases. She completed a Master’s in Biotechnological Applications at the University of Milan with summa cum laude honors, and a degree in Biological Sciences, majoring in Molecular Biology, also with summa cum laude, from the same university. Early in her career, she trained at the Mario Negri Institute’s Laboratory of Neurodegenerative Disorders, under Dr. Gianluigi Forloni, where she developed her expertise in prion biology, neurotoxicity, and mechanisms underlying neurodegenerative diseases.

Experience 

Assoc. Prof. Dr. Luana Fioriti has held prominent academic and research positions in both Italy and the United States. She currently serves as Head of Laboratory at the Department of Neuroscience, Mario Negri Institute, Milan, and Adjunct Associate Research Scientist at Columbia University. She has conducted extensive work in the laboratories of Nobel Laureate Eric Kandel and Dr. Ottavio Arancio at Columbia. Previously, she was an Associate Research Scientist at the Howard Hughes Medical Institute. Her career reflects a consistent focus on molecular neuroscience, protein biology, and translational approaches to neurodegenerative disorders, combining leadership, mentorship, and cross-institutional scientific collaboration.

Awards and Honors 

Assoc. Prof. Dr. Luana Fioriti has been recognized with numerous fellowships and awards for her contributions to neuroscience. Early in her career, she received fellowships from the University of Milan, the Italian Institute for University Study, and the Mario Negri Institute. She was awarded a scholarship to present at the World Alzheimer Congress and fellowships from Fondazione Monzino and the Italian Academy for Advanced Studies at Columbia University. She earned the Columbia Mentorship Award, the Telethon Career Development Award, and the AIMS Award for identifying SARS-CoV-2 protein inhibitors. These honors highlight her outstanding research leadership and impact in neurobiology.

Research Focus 

Assoc. Prof. Dr. Luana Fioriti research focuses on the molecular mechanisms of neurodegenerative diseases and memory persistence, with a particular emphasis on prion-like proteins, SUMOylation, ubiquitination, and tau pathology. Her work explores how protein aggregation and regulation influence synaptic plasticity and memory storage, contributing to both normal physiology and disease pathology. She has advanced understanding of prion biology, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. Through translational neuroscience, she investigates SUMO mimetics and small molecules as therapeutic candidates for dementia and other neurodegenerative disorders. Her research integrates cell models, animal systems, and cutting-edge molecular approaches to identify potential drug targets.

Publication Top Notes

Coiled-Coil Structures Mediate the Intercellular Propagation of Huntingtin

SARS-CoV-2 Nucleocapsid Protein Induces Tau Pathological Changes That Can Be Counteracted by SUMO2

Structure of a reversible amyloid fibril formed by the CPEB3 prion-like domain reveals a core sequence involved in translational regulation

A Combined Cell-Worm Approach to Search for Compounds Counteracting the Toxicity of Tau Oligomers In Vivo

Liquid-Liquid Phase Separation in Physiology and Pathophysiology of the Nervous System

Ubiquitination and SUMOylation of amyloid and amyloid-like proteins in health and disease

Neuronal Localization of SENP Proteins with Super Resolution Microscopy

CPEB3 inhibits translation of mRNA targets by localizing them to P bodies

Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain

SUMOylation Is an Inhibitory Constraint that Regulates the Prion-like Aggregation and Activity of CPEB3

The Persistence of Hippocampal-Based Memory Requires Protein Synthesis Mediated by the Prion-like Protein CPEB3

Conclusion

Based on her extensive and innovative contributions in neuroscience, neurodegenerative disorders, and translational molecular biology, Dr. Luana Fioriti is an excellent candidate for the Best Researcher Award. Her ability to integrate fundamental discoveries with therapeutic implications, coupled with her international recognition, patents, and leadership in cutting-edge research, make her highly deserving of this honor. With continued expansion of her global visibility and interdisciplinary collaborations, she is poised to make even greater contributions to the scientific community and global health.

Basavaraj Vastrad | Pharmaceutical Biotechnology | Best Innovation Award

Published on by Top Pharmaceutical

Dr. Basavaraj Vastrad | Pharmaceutical Biotechnology | Best Innovation Award

Associate Professor at KLE College of Pharmacy | India

Dr. Basavaraj Vastrad is a distinguished researcher in biochemistry, pharmaceutical biotechnology, and bioinformatics, with expertise spanning drug discovery, biomarker identification, molecular biology, and microbial techniques. His academic journey and scientific contributions reflect a strong commitment to advancing medical and pharmaceutical sciences. He has made significant strides in bioinformatics-driven research, particularly in understanding neurodegenerative and metabolic diseases through next-generation sequencing and computational biology approaches. With a strong foundation in microbiology, tissue culture, and molecular techniques, Dr. Vastrad bridges experimental science with computational tools. His research has resulted in impactful publications, addressing global health challenges and advancing translational medicine.

Publication Profile 

Google Scholar

Education 

Dr. Basavaraj Vastrad earned his Ph.D. in Biochemistry from Kuvempu University, where he focused on antibiotic production and optimization using solid-state fermentation. He holds an M. Pharm in Pharmaceutical Biotechnology from J.S.S. College of Pharmacy, Ootacamund, affiliated with The Tamilnadu Dr. M.G.R Medical University, where he gained expertise in microbial, molecular, and tissue culture techniques. He began his academic foundation with a B. Pharmacy degree from K.L.E’s College of Pharmacy under RGUHS, Bangalore. Earlier, he completed his P.U.C-II at Karnataka Science College, Dharwad, and his S.S.L.C. at Karnataka High College, Dharwad, establishing a solid base in science and medicine.

Experience 

Dr. Basavaraj Vastrad has extensive research experience in pharmaceutical biotechnology, biochemistry, and bioinformatics. His M. Pharm work encompassed microbial assays, enzyme characterization, fermentation technology, cytotoxicity studies, antiviral and antioxidant assays, and tissue culture methods. During his doctoral program, he investigated solid-state fermentation for antibiotic production using agricultural residues, optimizing growth conditions and characterizing bioactive compounds through advanced analytical methods. His expertise extends to next-generation sequencing, microarray analysis, and biomarker discovery, contributing to translational research in neurodegenerative and metabolic diseases. Through bioinformatics-driven projects, Dr. Vastrad has made critical discoveries in molecular pathways and therapeutic targets, resulting in several impactful publications.

Awards and Honors 

Dr. Basavaraj Vastrad has been recognized for his contributions to pharmaceutical biotechnology, bioinformatics, and biomedical research. His work on disease biomarker identification and next-generation sequencing analysis has earned appreciation in the scientific community, leading to high-quality publications in reputed international journals. His doctoral research on antibiotic production through solid-state fermentation was highly regarded for its potential industrial applications. He has also been acknowledged for his collaborative research on Alzheimer’s, Parkinson’s, Huntington’s disease, and metabolic disorders. With impactful publications, peer recognition, and contributions to translational science, Dr. Vastrad stands as a promising candidate for research awards and academic distinction.

Research Focus 

Dr. Basavaraj Vastrad research focuses on the intersection of biotechnology, molecular biology, and bioinformatics. His expertise lies in identifying disease-associated genes, pathways, and biomarkers through computational and next-generation sequencing data analysis. He has explored the molecular underpinnings of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s disease, dementia, and metabolic disorders like gestational diabetes mellitus. His doctoral research emphasized antibiotic production through solid-state fermentation, while his M. Pharm training provided strong grounding in microbial, enzymatic, and cell culture techniques. Currently, his bioinformatics-driven studies integrate systems biology with molecular docking to propose potential therapeutic compounds for complex human diseases.

Publication Top Notes

Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data

Optimization and production of neomycin from different agro industrial wastes in solid state fermentation

Identification of candidate biomarkers and therapeutic agents for heart failure by bioinformatics analysis

Bioinformatics analyses of significant genes, related pathways, and candidate diagnostic biomarkers and molecular targets in SARS-CoV-2/COVID-19

Identification of crucial candidate genes and pathways in glioblastoma multiform by bioinformatics analysis

Optimization of process parameters for rifamycin b production under solid state fermentation from Amycolatopsis mediterranean MTCC14

Identification of potential mRNA panels for severe acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment using microarray dataset and bioinformatics methods

Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules

Identification of important invasion and proliferation related genes in adrenocortical carcinoma

Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules

Identification of candidate biomarkers and pathways associated with type 1 diabetes mellitus using bioinformatics analysis

Identification of key pathways and genes in obesity using bioinformatics analysis and molecular docking studies

Analysis of differentially expressed genes in coronary artery disease by integrated microarray analysis

Conclusion

Based on his strong academic foundation, diverse methodological expertise, and influential research publications in neurodegenerative, metabolic, and reproductive disorders, Dr. Basavaraj Vastrad is a highly suitable candidate for the Research for Best Innovation Award. His pioneering bioinformatics-driven approaches to unravel disease mechanisms and identify biomarkers showcase a forward-thinking vision aligned with global health challenges. With additional focus on translational research and clinical applications, he has the potential to emerge as a leading innovator in pharmaceutical biotechnology and precision medicine.

Kamini Raghuram | Drug Safety and Risk Management | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Kamini Raghuram | Drug Safety and Risk Management | Best Researcher Award

Staff Neonatologist and Developmental Pediatrician at University of Toronto | Canada

Dr. Kamini Raghuram is a clinician-scientist specializing in developmental and behavioral pediatrics, neonatal-perinatal medicine, and clinical epidemiology. With a strong foundation in pediatrics, she has combined clinical expertise with cutting-edge research to advance outcomes in high-risk and preterm infants. Her work bridges clinical practice, epidemiology, and innovative technological tools such as automated video-based analysis for motor impairment. Dr. Raghuram has been a principal and co-investigator on numerous funded projects and has published extensively in leading pediatric and neonatal journals. She is widely recognized for her dedication to improving long-term neurodevelopmental outcomes in vulnerable infant populations.

Publication Profile 

Orcid

Education 

Dr. Kamini Raghuram completed her Doctor of Medicine (MD) at the University of Toronto, followed by FRCPC training in General Pediatrics, Neonatal and Perinatal Medicine, and Developmental and Behavioral Pediatrics at the same institution. She earned a Master of Science in Clinical Epidemiology and Health Care Research from the Institute of Health Policy, Management, and Evaluation, University of Toronto, where her thesis focused on video-based motor impairment analysis in preterm infants. Earlier, she obtained a Bachelor of Applied Science in Chemical and Biological Engineering from the University of British Columbia, graduating as class valedictorian and recognized for outstanding research proficiency.

Experience 

Dr. Kamini Raghuram has held extensive clinical and academic positions across pediatrics, neonatology, and developmental medicine. She has served as a clinician-investigator, integrating patient care with translational research to develop evidence-based approaches for preterm infants. Her work includes leading clinical trials, advancing quality improvement initiatives, and applying machine learning and automated video analysis for early detection of motor and neurodevelopmental impairments. With expertise spanning neonatal intensive care, developmental follow-up, and health outcomes research, she has collaborated nationally and internationally to improve clinical pathways for high-risk infants. Her experience reflects a unique combination of bedside practice and pioneering research in pediatrics.

Awards and Honors 

Dr. Kamini Raghuram has received numerous awards and funding recognitions for her research and clinical excellence. These include CIHR grants exceeding $2 million, innovation fund competitions, and recognition for her work on neonatal outcomes. She has won presentation and research awards at the University of Toronto, The Hospital for Sick Children, and international conferences. Honors such as the Excellence in Academic Coaching Award, Quality Improvement Award, Canada Graduate Scholarship, and early-career fellowships highlight her leadership and academic impact. Earlier, as an engineering student, she received the Lefevre Gold Medal and delivered the valedictorian address at the University of British Columbia.

Research Focus 

Dr. Kamini Raghuram research focuses on improving neurodevelopmental and health outcomes in preterm and high-risk infants through early detection, intervention, and long-term follow-up strategies. She applies advanced tools, including automated video analysis, MRI biomarkers, and large-scale database studies, to identify predictors of motor and cognitive impairment. Her work integrates clinical epidemiology with neonatal and developmental pediatrics, emphasizing translational approaches from bench to bedside. She is also involved in clinical trials addressing interventions such as coadministration therapies and surgical decision-making in fetal medicine. Her ultimate goal is to enhance early diagnosis, optimize interventions, and improve quality of life for vulnerable children.

Publication Top Notes

Caregiver Experiences, Healthcare Provider Perspectives and Child Outcomes with Virtual Care in a Neonatal Neurodevelopmental Follow-Up Clinic: A Mixed-Methods Study

Automated Movement Analysis to Predict Cerebral Palsy in Very Preterm Infants: An Ambispective Cohort Study

Conclusion

Dr. Kamini Raghuram is a highly deserving candidate for the Best Researcher Award. Her career reflects a rare combination of clinical excellence, research innovation, and dedication to improving outcomes for preterm infants. With substantial grant funding, groundbreaking studies in automated movement analysis, and leadership in advancing neonatal care, she exemplifies the qualities of a leading researcher. While opportunities exist to expand her global influence and further scale her innovations, her proven track record of impactful, patient-centered research makes her an outstanding nominee for this prestigious recognition.

Dmitry Gushchin | Gene Therapy | Lifetime achievement Award

Published on by Top Pharmaceutical

Dr. Dmitry Gushchin | Gene Therapy | Lifetime Achievement Award

Lead scientist at Sirius University of Science and Technology | Russia

Dr. Dmitry Gushchin is a molecular biologist and genome engineering expert with over three decades of international research and leadership experience. He has made pioneering contributions to CRISPR systems, zinc-finger nucleases, and chromatin biology. Currently serving as Lead Scientist at Sirius University of Science and Technology, he leads translational medicine and colloidal medicine research. His career spans prominent institutions including Sangamo BioSciences, NIH, École Polytechnique, and the Institute for Basic Science. Dr. Gushchin has authored numerous high-impact publications, holds multiple U.S. patents, and has significantly advanced technologies in gene editing, cancer biology, and translational medicine with global scientific impact.

Publication Profile 

Google Scholar

Education 

Dr. Dmitry Gushchin earned his Master of Science in Molecular and Chemical Physics from the Moscow Institute of Physics and Technology, where he developed a strong foundation in biophysics and molecular mechanisms. He completed his Ph.D. in the Chromosome Structure Laboratory at the Engelhardt Institute of Molecular Biology, Moscow, focusing on chromatin biology and the role of histone modifications in transcriptional regulation. His academic training combined rigorous molecular biology, genome regulation, and structural biochemistry, which later evolved into groundbreaking applied research in gene editing technologies. This strong educational foundation equipped him to bridge fundamental biology with advanced translational medicine applications.

Experience 

Dr. Dmitry Gushchin has held key scientific positions worldwide, including Lead Scientist at Sirius University, Assistant Professor at Nazarbayev University, and Senior Research Scientist at the Moscow Institute of Physics and Technology. His career also includes impactful roles as Research Engineer at École Polytechnique, Research Fellow at the Institute for Basic Science in Korea, and Scientist at Sangamo BioSciences, where he co-authored more than 20 peer-reviewed articles and obtained 10 U.S. patents. Earlier roles include visiting scientist positions at NIH, Argonne National Laboratory, and Imperial Cancer Research Fund, where he contributed to discoveries in chromatin biology, interferon signaling, and genome engineering.

Awards and Honors 

Dr. Dmitry Gushchin scientific excellence has been recognized through multiple achievements and honors. At Sangamo BioSciences, he obtained 10 U.S. patents for innovations in genome mutation detection and targeted deletions with zinc-finger nucleases. His pioneering research has been published in top journals such as Nature, Cell, Science, and Nature Biotechnology. He contributed to developing CRISPR-Cpf1 systems with new PAM specificities and established key methods for base editing. His discoveries in interferon signaling and nucleosome mobilization have been highly influential. In addition, he received competitive international funding, including grants for whole-genome screening in oncology, underscoring his role as a leading innovator in biomedicine.

Research Focus 

Dr. Dmitry Gushchin research focuses on genome engineering, translational medicine, and molecular mechanisms of disease. He has developed cutting-edge technologies in gene editing, including zinc-finger nucleases, CRISPR-Cpf1 systems, and base editing strategies. His work advances cancer biology through functional studies on tumor cell motility, knockout models, and circulating tumor DNA biomarkers. In translational medicine, he integrates nanotechnology, colloidal systems, and genetic tools for precision therapy. He also explores chromatin regulation, interferon signaling, and epigenetic dynamics. By combining fundamental molecular biology with applied biomedical innovation, Dr. Gushchin drives progress in personalized medicine, cancer therapeutics, and next-generation genetic engineering strategies.

Publication Top Notes

An improved zinc-finger nuclease architecture for highly specific genome editing

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

The protein tyrosine kinase JAK1 complements defects in interferon-α/β and-γ signal transduction

Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations

DNA analysis and diagnostics on oligonucleotide microchips.

A rapid and general assay for monitoring endogenous gene modification

A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin‐6.

Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-& gamma; signal transduction pathway

Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases

Oligonucleotide microchips as genosensors for determinative and environmental studies in microbiology

Chromatin structural features and targets that regulate transcription

Translating dosage compensation to trisomy 21

Manual manufacturing of oligonucleotide, DNA, and protein microchips

Conclusion

Dr. Dmitry Gushchin embodies the qualities of a scientist whose career achievements merit recognition through the Research Lifetime Achievement Award. His groundbreaking innovations in genome engineering, molecular medicine, and translational research have advanced the frontiers of biotechnology and medical science. While there is potential for even greater global visibility and clinical translation, his sustained excellence, pioneering discoveries, and international scientific contributions make him an outstanding candidate for this distinguished honor.

Sarah Eliuth Ochoa Hugo | Nanomedicine | Young Scientist Award

Published on by Top Pharmaceutical

Dr. Sarah Eliuth Ochoa Hugo | Nanomedicine | Young Scientist Award

Dr. Sarah Eliuth Ochoa Hugo at Center of Research and Assistance in Technology and Design of the State of Jalisco| Mexico

Dr. Sarah Eliuth Ochoa Hugo is a dedicated pharmaceutical chemist, biotechnologist, and researcher specializing in medical and pharmaceutical innovation. Currently pursuing her Ph.D. in Biotechnological Innovation Applied to Health at CIATEJ, she integrates her expertise in biotechnology, nanotechnology, and pharmacology to address critical challenges in cancer, Alzheimer’s disease, and medical device safety. As a lecturer at Universidad del Valle de México, she mentors future health professionals, guiding them in scientific research and publication. Alongside academia, she engages in entrepreneurial initiatives that merge scientific innovation with social impact, demonstrating her commitment to advancing healthcare through research, education, and applied technology.

Publication Profile 

Orcid

Education 

Dr. Sarah Eliuth Ochoa Hugo is currently a Ph.D. candidate in Biotechnological Innovation Applied to Health at CIATEJ, focusing on advanced biomedical solutions. She previously earned her Master of Science in Biotechnological Innovation Applied to Medical and Pharmaceutical Sciences at CIATEJ, where her thesis explored exosomal cargo in Alzheimer’s pathogenesis. Her academic foundation was built at Universidad del Valle de México, where she completed a Bachelor of Science in Pharmaceutical Chemistry and Biotechnology. There, she validated a 3D glioblastoma multiforme culture model. Complementing her degrees, she has completed certifications in pharmaceutical regulation, medical English, cancer biology, pharmacology, and advanced English proficiency.

Experience 

Dr. Sarah Eliuth Ochoa Hugo serves as an undergraduate lecturer in Health Sciences at Universidad del Valle de México, where she promotes research-oriented learning and student publications. She is co-founder of Quality Approvers, a startup advancing process optimization using Lean and Six Sigma methodologies. Previously, she worked as a Pharmaceutical Chemist and Assistant Sanitary Responsible at San Javier Hospital, ensuring pharmaceutical compliance and safety. During the pandemic, she launched Paihuenk, a social entrepreneurship project producing artisanal cosmetics to support local communities. With extensive academic and industry experience, she bridges biomedical research, pharmaceutical practice, and innovation-driven entrepreneurship in health and biotechnology.

Awards and Honors 

Dr. Sarah Eliuth Ochoa Hugo achievements are reflected through her strong academic and research portfolio, including international presentations at the Society for Neuroscience meetings in San Diego and publications in prominent journals. Her certification by COFEPRIS in pharmaceutical dispensing underscores her compliance with industry standards, while academic training from King’s College London, Monash University, and Johns Hopkins has expanded her global expertise. At Universidad del Valle de México, she has been recognized for her excellence in teaching, demonstrated. Her contributions to translational research and community-focused entrepreneurship highlight her growing academic influence.

Research Focus 

Dr. Sarah Eliuth Ochoa Hugo research focuses on cancer therapy, Alzheimer’s disease, and medical device vigilance through biotechnological innovation. She has explored 3D glioblastoma culture models, evaluated phenolic compounds for anticancer activity, and investigated exosomal cargo in Alzheimer’s disease. Her recent work integrates nanotechnology, particularly gold nanostructures, for photothermal therapies in colon cancer. Additionally, she contributes to medical device monitoring and pharmaceutical safety through technovigilance research. Her multidisciplinary approach combines molecular biology, pharmacology, and nanomedicine, aiming to design innovative therapies with clinical applications. By integrating biotechnology with applied health sciences, her work advances precision medicine, preventive care, and translational biomedical innovation.

Publication Top Notes

Xiao Sheng | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Xiao Sheng | Drug Discovery and Development | Best Researcher Award

lecturer at Naval Medical University School of Pharmacy | China

Dr. Xiao Sheng is a distinguished researcher in biochemistry and molecular biology at the Navy Medical University, China. His work bridges traditional Chinese medicine, molecular signaling, and intestinal health, with a focus on aging and regenerative biology. As a principal investigator of multiple funded projects, he has made significant contributions to understanding mechanisms of intestinal stem cell regulation, tumor progression, and herbal medicine efficacy. His publications in high-impact journals highlight pioneering findings in antioxidant pathways, stem cell biology, and gut regeneration. Dr. Xiao is actively engaged in international collaborations, scientific societies, and editorial responsibilities in biomedical research.

Publication Profile 

Orcid

Education 

Dr. Xiao Sheng completed his academic training in biochemistry and molecular biology, developing a strong foundation in cellular and molecular research. At the Navy Medical University, he pursued advanced education integrating biomedical sciences with translational research approaches. His education emphasized experimental medicine, molecular signaling pathways, and the application of traditional Chinese medicine concepts within modern biological frameworks. This interdisciplinary training enabled him to explore the interaction between cellular metabolism, intestinal regeneration, and aging biology. His academic preparation laid the groundwork for his later success as a principal investigator and contributed to his leadership in national and international scientific initiatives.

Experience 

Dr. Xiao Sheng  has extensive experience leading research in biochemistry, molecular biology, and translational medicine. As principal investigator, he heads projects supported by Anhui Provincial Engineering Technology Research Center and the Second Military Medical University, focusing on intestinal injury repair, tumor biology, and herbal medicine. His work extends to national research initiatives such as the National Key R&D Program and the National Natural Science Foundation of China, where he has contributed as a key participant. He has authored numerous peer-reviewed publications, serves on editorial boards, and holds active memberships in professional committees, advancing biomedical research and international scientific collaboration.

Awards and Honors 

Dr. Xiao Sheng has received multiple recognitions for his scientific contributions. He earned the Outstanding Poster Award at the International and Chinese Drosophila Biology Congress, demonstrating the novelty of his research in model organisms. His innovative approaches to Chinese medicine research were honored with the Third Prize in the Traditional Chinese Medicine Group at the National Undergraduate Forum on Innovative Research in Basic Medicine and Experimental Design. Recently, he was named a “Shizhen Scholar,” reflecting his leadership and excellence in integrating traditional medicine with modern molecular biology. These awards underscore his contributions to translational and interdisciplinary biomedical research.

Research Focus 

Dr. Xiao’s  Sheng  research centers on molecular mechanisms regulating intestinal stem cell biology, aging, and regenerative medicine. He explores how herbal medicine compounds influence cellular pathways, particularly the Keap1–Nrf2 signaling axis, to mitigate intestinal injury and aging-related disorders. His studies extend to tumor biology, focusing on how nuclear lamina proteins drive cancer development through cell competition. Additionally, he investigates molecular regulators of gut regeneration, including transcription factors and RNA modifications. His interdisciplinary approach combines traditional Chinese medicine with modern molecular biology, advancing novel therapeutic strategies. His work holds promise for improving treatments for age-related diseases and metabolic disorders.

Publication Top Notes

Unlocking nature’s medicine cabinet through Drosophila–Driven exploration

Werner syndrome exonuclease promotes gut regeneration and causes age-associated gut hyperplasia in Drosophila

Phase separation of BuGZ regulates gut regeneration and aging through interaction with m6A regulators

Antioxidant Effects of Caffeic Acid Lead to Protection of Drosophila Intestinal Stem Cell Aging

Aging-related upregulation of the homeobox gene caudal represses intestinal stem cell differentiation in Drosophila

Denise Faustman | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Denise Faustman | Immunotherapy | Best Researcher Award

Associate Professor of Medicine at Harvard Medical School  | United States

Dr. Denise Faustman is a physician-scientist recognized for her pioneering work in immunology, autoimmunity, and type 1 diabetes research. She serves as Director of the Immunobiology Laboratory at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Her career bridges clinical medicine, molecular biology, and translational research, with a focus on advancing novel therapies for autoimmune diseases. Dr. Faustman has significantly contributed to understanding immune tolerance, vaccine-based interventions, and the role of BCG vaccination in autoimmune modulation. She is widely respected for her leadership, scientific advisory roles, and commitment to women’s health and immunological innovation.

Publication Profile 

Scopus

Education

Dr. Denise Faustman earned a B.S. in Zoology and Chemistry from the University of Michigan, followed by an M.D. and Ph.D. in Molecular and Cellular Biology from Washington University School of Medicine in St. Louis. She completed her postdoctoral training in transplantation immunology at Washington University before pursuing clinical training in internal medicine and endocrinology at Massachusetts General Hospital and Harvard Medical School. Her combined training in medicine, molecular biology, and immunology has uniquely positioned her to integrate clinical insights with advanced laboratory science, fueling her translational research on autoimmunity, immunotherapy, and novel strategies for the treatment of chronic diseases.

Experience 

Dr. Denise Faustman has built a distinguished career at Harvard Medical School and Massachusetts General Hospital, where she directs the Immunobiology Laboratory. Her academic roles span from Instructor to Associate Professor of Medicine, combined with leadership in clinical and translational immunology. She has served on numerous national and international scientific committees, including advisory roles at the FDA, NIH, NAS, and Institute of Medicine. As a physician-scientist, she bridges patient care with laboratory innovation, advancing novel treatments for autoimmune diseases. She has also provided scientific leadership for biotech companies, foundations, and research councils, shaping biomedical policy, discovery, and translational impact.

Awards and Honors 

Dr. Denise Faustman contributions have been recognized through prestigious appointments and leadership roles. She has served as Chair and Board Member of the Society for Women’s Health Research, Advisory Committee Member for the FDA, and Chair of national immunology and autoimmunity symposia. She has been elected to scientific advisory boards for biotechnology companies and foundations worldwide, including Sjögren’s Syndrome Foundation and Farallone Therapeutics. Her expertise has been sought by NASA, NIH, and the Department of Defense for defining priorities in immunology, vaccine safety, and women’s health. These roles reflect her influence, innovation, and leadership in advancing immunological and biomedical sciences.

Research Focus 

Dr. Denise Faustman research centers on autoimmunity, immune regulation, and translational immunotherapy. Her laboratory is internationally recognized for pioneering studies on immune tolerance and the use of BCG vaccine as a potential therapy for type 1 diabetes. She investigates mechanisms of T cell regulation, biomarkers for autoimmune progression, and pathways of immune modulation to translate discoveries into clinical applications. Her work bridges fundamental immunology with patient-centered research, aiming to develop safe, effective, and durable treatments for chronic autoimmune diseases. By integrating laboratory science, clinical trials, and translational medicine, Dr. Faustman is shaping innovative therapeutic strategies with global health impact.

Publication Top Notes

The spleen assumes a major role in blood glucose regulation in type 1 diabetes patients treated with BCG

Late in the US pandemic, multi-dose BCG vaccines protect against COVID-19 and infectious diseases

Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer

Association of BCG Vaccine Treatment with Death and Dementia in Patients with Non-Muscle-Invasive Bladder Cancer

TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4+Foxp3+ regulatory T cells

Letter to the Editor Regarding “The Non-Significant Benefit of BCG Vaccination for the Treatment of Iranian Patients with Type 1 Diabetes up to 48 Weeks: A Controversial Result”

The benefits of clustering in TNF receptor superfamily signaling

Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies

BCG vaccinations drive epigenetic changes to the human T cell receptor: Restored expression in type 1 diabetes

Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes

Maria Garrido | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Dr. Maria Garrido | Personalized Medicine | Women Researcher Award

Doctor at Hospital Universidtario 12 de octubre-Universidad Complutense de Madrid | Spain

Dr. Maria Garrido is a physician-scientist specializing in pathology and translational oncology with a focus on melanoma and cutaneous lymphomas. She earned her medical degree from the University of Granada and her PhD in Health Sciences and Biomedicine from Universidad Complutense de Madrid. With extensive international experience at the University of California San Francisco and Memorial Sloan Kettering, her research has contributed to landmark discoveries in oncogenes, fusion kinases, and tumor biomarkers. She currently works in dermatopathology and oncology research, collaborating with leading groups in Europe and internationally to advance personalized cancer diagnostics and therapeutic strategies.

Publication Profile 

Orcid

Education 

Dr. Maria Garrido obtained her medical degree in Medicine and Surgery from the University of Granada. She pursued her residency in Anatomical Pathology at Hospital Universitario 12 de Octubre, Madrid, and later completed a PhD in Health Sciences and Biomedicine at Universidad Complutense de Madrid. Complementing her medical and scientific training, she earned a Master’s in Clinical Management, Medical, and Healthcare Leadership from Universidad Tecnológica. Her academic formation integrates rigorous clinical foundations with molecular oncology research, allowing her to bridge patient care and translational science. She has continued to enhance her expertise through national and international academic fellowships.

Experience 

Dr. Maria Garrido has served as a resident and clinical specialist in pathology at major Spanish hospitals, including Hospital 12 de Octubre, Hospital General de Móstoles, and Clinic Hospital of Barcelona. Internationally, she was a fellowship researcher at UCSF and Memorial Sloan Kettering, contributing to melanoma genetics and translational oncology. She has collaborated on groundbreaking discoveries, including oncogenes in uveal melanoma and fusion kinases in Spitz tumors. Currently, she is part of the dermatopathology and oncology research group at Hospital Universitario 12 de Octubre, Madrid, where she advances studies on melanoma, lymphomas, molecular biomarkers, and diagnostic innovations in cutaneous oncology.

Awards and Honors 

Dr. Maria Garrido has received notable recognition for her research contributions. She was awarded a mobility fellowship by the Spanish Ministry of Science and Innovation for professional development in computational pathology at Queen’s University, Belfast. Her discoveries, including the GNA11 oncogene and fusion kinases in melanocytic tumors, have been published in high-impact journals such as the New England Journal of Medicine, Nature Communications, and Nature Genetics. Her contributions to the field of melanoma genetics have been cited worldwide, shaping the understanding of tumor biology. She continues to be honored through invitations to collaborate on international research initiatives and networks.

Research Focus 

Dr. Maria Garrido research focuses on the molecular pathology of melanoma and cutaneous lymphomas. She has made significant contributions to identifying oncogenes such as GNA11 and GNAQ, which account for most uveal melanomas, and discovering kinase fusion proteins in Spitz tumors. Her work also includes genetic studies on desmoplastic melanoma highlighting NFKBIE mutations. More recently, she has contributed to refining the classification of cutaneous lymphomas and identifying new biomarkers to guide diagnosis, prognosis, and therapeutic response. Her approach integrates pathology, molecular biology, and translational medicine to improve personalized treatment strategies and enhance patient outcomes in oncology and dermatopathology.

Publication Top Notes

Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances

Acute sarcoidosis as a harbinger for pancreatic adenocarcinoma

TERT promoter mutation in sebaceous neoplasms

Orbital Solitary Fibrous Tumor: Four Case Reports—Clinical and Histopathological Features

Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review

SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma